Am Heart J

1. WEXLER DJ, Mayberry LS, Nelson LA, Lema-Driscoll J, et al
   Dual versus monotherapy with SGLT2 inhibitor and GLP-1 receptor agonist: PRECIDENTD pragmatic randomized trial.
   Am Heart J. 2026;294:107332.
   

   >> Share

   
   

   
   Am J Clin Nutr

2. FURST AJ, Johnson KE, Nagel EM, Yerabandi N, et al
   Gestational diabetes, human milk oligosaccharide (HMO) concentrations, and their links to infant weight gain and the gut microbiome in a United States observational cohort.
   Am J Clin Nutr. 2026 Feb 9:101235. doi: 10.1016/j.ajcnut.2026.101235.
   

   >> Share

   
   

   
   Am J Hypertens

3. LIU H, Lyu T, Wu Y, Zhao H, et al
   Hypertension and New-Onset atrial Fibrillation in Participants with Diabetes Mellitus: A Report from the Population-Based kailuan Study.
   Am J Hypertens. 2026 Feb 15:hpag011. doi: 10.1093.
   

   >> Share

   
   
4. LIWELEYA S, Siame L, Hamooya BM, Chota A, et al
   Reframing Insulin Resistance and Hypertension in type 2 Diabetes: Clinical and Mechanistic-Level Insights from Non-Insulin-Based Biomarkers.
   Am J Hypertens. 2026 Feb 14:hpag010. doi: 10.1093.
   

   >> Share

   
   

   
   Am J Nephrol

5. AN Y, Zhang H
   SGLT-2 Inhibitors: A Deeper Dive into Their Renal Protective Properties beyond Glycemic Control and Proteinuria Reduction.
   Am J Nephrol. 2026;57:53-65.
   

   >> Share

   
   

   
   Am J Ophthalmol

6. WU AL, Hao J, Gao L, Guo Y, et al
   Elevated Retinal Neovascularization on Widefield Optical Coherence Tomography Angiography Predicts Complications in High-Risk Proliferative Diabetic Retinopathy.
   Am J Ophthalmol. 2026;283:268-278.
   

   >> Share

   
   
7. ZHOU J, Lee DA, Talebi Y, Wu G, et al
   Risk of Dementia in Type 2 Diabetes Patients with Open-Angle Glaucoma: Insights from a Nationwide Real-World Cohort Study.
   Am J Ophthalmol. 2026 Feb 7:S0002-9394(26)00060.
   

   >> Share

   
   
8. SANCHEZ VMA
   Comment on: Potential eye disorders in people with and without Type 2 diabetes mellitus exposed to GLP-1 receptor agonists; an examination of the FAERS database.
   Am J Ophthalmol. 2026 Feb 9:S0002-9394(26)00061.
   

   >> Share

   
   
9. MURRAY M, Schifano F, Chiappini S, Corkery JM, et al
   Reply to comment on: "Potential eye disorders in people with and without Type 2 diabetes mellitus exposed to GLP-1 receptor agonists: an examination of the FAERS database" (Am J Ophthalmol. 2025 Dec 20;S0002-9394(25)00666-X).
   Am J Ophthalmol. 2026 Feb 10:S0002-9394(26)00062.
   

   >> Share

   
   
10. KHANGURA MS, Spratt MA, Gao A, Manhapra A, et al
    The Association Between Diabetic Retinopathy Severity and Dementia Risk: A TriNetX Longitudinal Cohort Study.
    Am J Ophthalmol. 2026 Feb 13:S0002-9394(26)00073.
    

    >> Share

    
    

    
    BMC Ophthalmol

11. ARYAL B, Acharya S, Sitaula S, Karki P, et al
    Corneal endothelial morphology in type 2 diabetes mellitus, a comparative study among Nepalese population.
    BMC Ophthalmol. 2026;26:83.
    

    >> Share

    
    

    
    Diabet Med

12. MICHAELS VR, Crocket HR, Boucsein A, Zhou Y, et al
    Experiences with Simplera sync all-in-one sensors and extended wear infusion sets in adolescents and young adults using the MiniMed 780G: A qualitative study.
    Diabet Med. 2026;43:e70197.
    

    >> Share

    
    
13. CIGLER M, Soholm U, Broadley M, Pouwer F, et al
    User evaluation of the Hypo-METRICS app: A tool for real-time symptom reporting of hypoglycaemia.
    Diabet Med. 2026;43:e70185.
    

    >> Share

    
    
14. LIN R, Wootton E, Gaca M, Venkatesh B, et al
    Hyperosmolar hyperglycaemic state: A systematic review of management guidelines and their evidence.
    Diabet Med. 2026;43:e70226.
    

    >> Share

    
    
15. HINDENES LB, Ruiz PL, Tapia G, Bakken IJ, et al
    Type 2 diabetes in Norway 2009-2021: Have declining incidence rates continued?
    Diabet Med. 2026 Feb 8:e70225. doi: 10.1111/dme.70225.
    

    >> Share

    
    
16. RAI A, Marshall J, Nandyala S, Her M, et al
    Post-authorization safety study to assess the risk of diabetic ketoacidosis among type 2 diabetes mellitus patients treated with ertugliflozin compared to patients treated with other antihyperglycaemic agents in a Medicare and Medicaid population.
    Diabet Med. 2026 Feb 9:e70208. doi: 10.1111/dme.70208.
    

    >> Share

    
    
17. POWELL PA, Frances SM, de Galan BE, Heller S, et al
    'There is more to life than HbA(1c)': A comprehensive qualitative framework from the Hypo-RESOLVE project evidencing the impacts of hypoglycaemia on the quality of life of adults living with type 1 or type 2 diabetes.
    Diabet Med. 2026 Feb 9:e70240. doi: 10.1111/dme.70240.
    

    >> Share

    
    
18. WARD JK, Shah MU, Lee K, Squires PE, et al
    Targeting inflammation in cardiometabolic disease: Icosapent ethyl modulates monocyte-derived macrophages isolated from patients with cardiovascular disease with or without type 2 diabetes.
    Diabet Med. 2026 Feb 9:e70247. doi: 10.1111/dme.70247.
    

    >> Share

    
    
19. ZAFAR A, Scarlata C, Jaleel N
    Chronic kidney disease in type 2 diabetes in UK primary care: Testing frequency, coding accuracy and clinical inertia.
    Diabet Med. 2026 Feb 12:e70254. doi: 10.1111/dme.70254.
    

    >> Share

    
    
20. SEIDU S, Baatiema L
    Where diabetes is rising fastest, the evidence is quietest: Why LMIC authorship matters.
    Diabet Med. 2026;43:e70234.
    

    >> Share

    
    
21. SIMS S, Stenov V, Due-Christensen M, Fisher L, et al
    Group-based interventions to reduce diabetes distress in adults with type 1 diabetes: A rapid realist review of the Reduce and TunedIn interventions.
    Diabet Med. 2026 Feb 12:e70242. doi: 10.1111/dme.70242.
    

    >> Share

    
    
22. GUO H, Guo Z, Liu Y, Zhang Q, et al
    Estimating the economic burden of diabetes in young adults: A global analysis based on the GBD 2021 and a value of statistical life year framework.
    Diabet Med. 2026 Feb 13:e70255. doi: 10.1111/dme.70255.
    

    >> Share

    
    
23. KOMAKI S, Nakai M, Matsuura Y, Yamamoto K, et al
    Association between diabetes and in-hospital outcomes in patients with metabolic dysfunction-associated steatotic liver disease hospitalized for cardiovascular disease: A nationwide database study.
    Diabet Med. 2026 Feb 15:e70250. doi: 10.1111/dme.70250.
    

    >> Share

    
    

    
    Diabetes Care

24. KEREM L, Guedalia J, Lipschuetz M, Sehtman-Shachar DR, et al
    Maternal Diabetes and Early Neurodevelopment: Differential Milestone Attainment in Offspring by Diabetes Type.
    Diabetes Care. 2026 Feb 12:dc252456. doi: 10.2337/dc25-2456.
    

    >> Share

    
    

    
    Diabetes Obes Metab

25. VAN BAAL L, Raess L, Mathew A, Lahner H, et al
    Accuracy and reliability of a continuous glucose monitoring system with a focus on hypoglycaemia.
    Diabetes Obes Metab. 2026;28:2166-2174.
    

    >> Share

    
    
26. MECANI R, Basta S, Baumann PM, Cigler M, et al
    In-flight glycaemic control using automated insulin delivery systems: A within-subject comparative pilot study.
    Diabetes Obes Metab. 2026;28:2159-2165.
    

    >> Share

    
    
27. JOUBERT M, Dreves B, Arnould T, Soussi A, et al
    Comparative accuracy of smartphone apps and a generative AI tool for carbohydrate counting: An independent bicentric study.
    Diabetes Obes Metab. 2026;28:2105-2112.
    

    >> Share

    
    
28. YAO K, Yang X, Lei S, Yin S, et al
    Trends and disparities in type 1 diabetes-related mortality in the United States, 1999-2023.
    Diabetes Obes Metab. 2026 Feb 12. doi: 10.1111/dom.70546.
    

    >> Share

    
    
29. MINAKATA Y, Miura M, Nakatake N, Masuzawa M, et al
    Real-world effectiveness and safety of tirzepatide in Japanese patients with type 2 diabetes: A multi-site retrospective study.
    Diabetes Obes Metab. 2026 Feb 12. doi: 10.1111/dom.70550.
    

    >> Share

    
    
30. PITT JP, Muller A, Nicholas C, McCarthy OM, et al
    Comparison of pharmacodynamics and pharmacokinetics of ultra-rapid-acting insulin aspart and rapid-acting insulin aspart around continuous moderate intensity exercise in adults with type 1 diabetes: A randomised controlled trial.
    Diabetes Obes Metab. 2026 Feb 10. doi: 10.1111/dom.70487.
    

    >> Share

    
    
31. 
    RETRACTION: Effects of GLP-1 Receptor Agonists on Cognitive Function in Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis Based on Randomized Controlled Trials.
    Diabetes Obes Metab. 2026 Feb 10. doi: 10.1111/dom.70552.
    

    >> Share

    
    
32. O'NEAL DN, Sartoretto A, Holt BA, Abu Dayyeh BK, et al
    Safety, feasibility, and dose-dependent metabolic effects of endoscopic duodenal pulsed electric field therapy in adults with type 2 diabetes: Results from two multicentre proof-of-concept studies.
    Diabetes Obes Metab. 2026 Feb 9. doi: 10.1111/dom.70533.
    

    >> Share

    
    
33. NGUYEN B, Quon S, Dhaliwal B, Warwas M, et al
    Early versus late initiation of long-acting insulin in paediatric and adult diabetic ketoacidosis: A systematic review and meta-analysis of randomised control trials.
    Diabetes Obes Metab. 2026 Feb 9. doi: 10.1111/dom.70542.
    

    >> Share

    
    
34. VERKET M, Buitkamp LF, Kanna NDD, Thomas A, et al
    Effects of coaching with data management system intervention or usual care on glycemic control in patients with type 2 diabetes: A multicentre, randomised controlled trial.
    Diabetes Obes Metab. 2026 Feb 9. doi: 10.1111/dom.70534.
    

    >> Share

    
    
35. GU JX, Huang J, Zhang AM, Wang ZW, et al
    Oxidised lipoproteins and the risk of type 2 diabetes mellitus: A 5-year cohort study on beta-cell dysfunction and prediabetes progression.
    Diabetes Obes Metab. 2026 Feb 9. doi: 10.1111/dom.70540.
    

    >> Share

    
    
36. LAI CWY, Kwok HHY, Ye J, Ng CS, et al
    Effectiveness of behavioural economics-based financial incentives and social feedback on glycaemic control and physical activity in adults with newly diagnosed type 2 diabetes: A randomised control trial.
    Diabetes Obes Metab. 2026 Feb 9. doi: 10.1111/dom.70541.
    

    >> Share

    
    
37. MECANI R, Basta S, Baumann PM, Cigler M, et al
    Performance of continuous glucose monitoring systems (CGMs) during commercial flights in T1DM: A within-subject comparative pilot study.
    Diabetes Obes Metab. 2026;28:2245-2254.
    

    >> Share

    
    
38. NOVODVORSKY P, Thieme L, Lankova I, Frankova S, et al
    Insulin therapy DE-intensificAtion with iGlarLixi: A phase 4, open-label, parallel-group randomised controlled trial.
    Diabetes Obes Metab. 2026;28:1817-1825.
    

    >> Share

    
    
39. TAJ S, Zuber M, Rashid M, Chhabra M, et al
    Injection-site and dermatologic reactions associated with glucagon-like peptide-1 receptor agonists: Insights from meta-analysis of randomised controlled trials and real-world evidence.
    Diabetes Obes Metab. 2026;28:1956-1971.
    

    >> Share

    
    
40. STONE J, Tripyla A, Scalise MC, Balmer ML, et al
    Taxonomic and functional shifts in the microbiome of severely obese, prediabetic patients: Ketogenic diet versus energy-matched standard diet.
    Diabetes Obes Metab. 2026;28:1826-1835.
    

    >> Share

    
    
41. ZHANG Q, Zhou Y, Fu L, Xing Z, et al
    Relationship between cardiometabolic index and worsening renal function in T2DM: Insights from machine learning, growth mixture modelling, and development of a web-based risk prediction tool.
    Diabetes Obes Metab. 2026;28:1899-1914.
    

    >> Share

    
    
42. SUNG KH, Yu J, Kim S, Kim MK, et al
    Glucose tolerance and mortality across 24 cancer types and stages: A K-CURE Nationwide registry study.
    Diabetes Obes Metab. 2026;28:2051-2060.
    

    >> Share

    
    
43. JIMENEZ-TEN HOEVEL C, Besora-Moreno M, Queral J, Llaurado E, et al
    Ultrasound and MRI abdominal fat distribution and its associations with metabolic conditions in adults with abdominal obesity.
    Diabetes Obes Metab. 2026;28:2061-2074.
    

    >> Share

    
    

    
    Diabetologia

44. BORBJERG MK, Mokhtar S, Sutedja N, Koster A, et al
    Association of corneal nerve parameters with nerve abnormalities and neuropathic pain in prediabetes and type 2 diabetes: the Maastricht Study.
    Diabetologia. 2026 Feb 10. doi: 10.1007/s00125-026-06676.
    

    >> Share

    
    
45. KATTNER N, Bashir A, Shaw JAM
    The emerging role of pancreatic exocrine fibrosis as a common aetiological driver of islet dysfunction and diabetes: opportunities for novel disease-modifying interventions.
    Diabetologia. 2026 Feb 10. doi: 10.1007/s00125-026-06678.
    

    >> Share

    
    
46. MARZINOTTO I, Bazzigaluppi E, Brigatti C, Martinenghi S, et al
    Feasibility and performance of minimal-volume capillary blood screening for type 1 diabetes and coeliac disease autoantibodies across all age groups: the UNISCREEN population study.
    Diabetologia. 2026 Feb 10. doi: 10.1007/s00125-026-06680.
    

    >> Share

    
    
47. ZIVKOVIC J, Mitter M, Theodorou D, Moser O, et al
    Exercise in type 1 diabetes: real-world data on glucose levels and hypoglycaemia risk from over 420,000 exercise sessions.
    Diabetologia. 2026 Feb 13. doi: 10.1007/s00125-026-06672.
    

    >> Share

    
    
48. BRUNASSO A, Lange NF, Poli S, Schiavon M, et al
    Novel deuterium metabolic imaging technique reveals distinct patterns of postprandial hepatic glucose homeostasis in individuals with type 1 diabetes and healthy control individuals: a case-control study.
    Diabetologia. 2026 Feb 13. doi: 10.1007/s00125-026-06677.
    

    >> Share

    
    
49. SEBRAOUI S, Englund O, Nyberg F, Carlsson A, et al
    Geospatial clustering of type 1 diabetes in Sweden: a cohort study based on all residential locations from birth to diagnosis.
    Diabetologia. 2026 Feb 16. doi: 10.1007/s00125-026-06675.
    

    >> Share

    
    

    
    Invest Ophthalmol Vis Sci

50. KREBS AK, Diaz D, Sassani JW, Zagon IS, et al
    Mitigation of Oxidative Stress Pathways in the Diabetic Cornea and Lacrimal Glands Contributes to the Rapid Reversal of Diabetic Dry Eye by Naltrexone.
    Invest Ophthalmol Vis Sci. 2026;67:23.
    

    >> Share

    
    

    
    J Clin Endocrinol Metab

51. TOSUR M, Wierzchowska-McNew RA, Deutz NEP, Engelen MPKJ, et al
    Impaired Arginine, Citrulline and Glutamine Metabolism in Type 2 Diabetes: Insights from a Stable Isotope Study.
    J Clin Endocrinol Metab. 2026 Feb 7:dgag055. doi: 10.1210.
    

    >> Share

    
    
52. KASHER MERON M, Hornik-Lurie T, Twig G, Rotman-Pikielny P, et al
    GLP-1 receptor agonists and the risk of fragility fractures in older adults with type 2 diabetes.
    J Clin Endocrinol Metab. 2026 Feb 10:dgag056. doi: 10.1210.
    

    >> Share

    
    
53. ORTIZ ROCHA A, Kalavalapalli S, Godinez Leiva E, Barb D, et al
    Severity of MASH Activity by Iron-Corrected MRI Predicts Insulin Resistance and Cardiometabolic Risk in Type 2 Diabetes.
    J Clin Endocrinol Metab. 2026 Feb 11:dgag042. doi: 10.1210.
    

    >> Share

    
    

    
    J Clin Invest

54. NAIK AS, Alakwaa FM, Nair V, McCown PJ, et al
    Metabolic surgery mitigates early kidney injury in obese youth with diabetes by suppressing mTORC1/JAK-STAT signaling.
    J Clin Invest. 2026 Feb 3:e198545. doi: 10.1172/JCI198545.
    

    >> Share

    
    

    
    J Diabetes Complications

55. STEFANOU MI, Tentolouris A, Panagiotopoulos E, Theodorou A, et al
    Effects of GLP-1 receptor agonists on vascular dementia: a systematic review and meta-analysis.
    J Diabetes Complications. 2026;40:109271.
    

    >> Share

    
    
56. BALDASSARRE MPA, Carrieri F, Coluzzi S, D'Ascanio F, et al
    Modulation of circulating extracellular vesicles by antihyperglycemic therapies: A pilot randomized controlled trial.
    J Diabetes Complications. 2026;40:109273.
    

    >> Share

    
    
57. WEINGOLD R, Filippatos G, Anker SD, Wanner C, et al
    Finerenone increases the likelihood of improved KDIGO risk category in patients with CKD and type 2 diabetes: An analysis from FIDELITY.
    J Diabetes Complications. 2026;40:109274.
    

    >> Share

    
    

    
    J Hypertens

58. IKRAM J, Ali A, Huma S, Shah SW, et al
    Intensive versus routine blood pressure control in patients with type 2 diabetes: a meta-analysis and trial sequential analysis.
    J Hypertens. 2026 Feb 10. doi: 10.1097/HJH.0000000000004267.
    

    >> Share

    
    

    
    Lancet

59. GROARKE EM, Turturice B, Patel BA, Quinn KA, et al
    VEXAS syndrome: a comprehensive review of pathogenesis, clinical spectrum, and therapeutic strategies.
    Lancet. 2026;407:637-648.
    

    >> Share

    
    
60. ALNIMA T, Smits MM
    Response to STRIDE: semaglutide in peripheral artery disease and type 2 diabetes.
    Lancet. 2026;407:573.
    

    >> Share

    
    
61. BONACA MP, Nordanstig J, Ludvik B, Videmark A, et al
    Response to STRIDE: semaglutide in peripheral artery disease and type 2 diabetes - Authors' reply.
    Lancet. 2026;407:573-574.
    

    >> Share

    
    

    
    Metabolism

62. GERLACH PA, Gadgaard S, Madsen JS, Lindquist P, et al
    Global glucagon-like peptide-2 receptor activation linked to increased obesity risk in the UK Biobank.
    Metabolism. 2026 Jan 8:156489. doi: 10.1016/j.metabol.2025.156489.
    

    >> Share

    
    
63. PANUNZI S, Russo S, Pompa M, De Gaetano A, et al
    Personalizing bariatric metabolic surgery: Predictors of weight-loss success and risk of weight recurrence.
    Metabolism. 2026;177:156495.
    

    >> Share

    
    
64. MUZUROVIC E, Katsiki N, Volcansek S, Plescia F, et al
    Emerging incretin- and multi-agonist-based treatments - the continued refinement and continuous expansion of a potent therapeutic armamentarium for cardio-kidney-liver-metabolic diseases and beyond.
    Metabolism. 2026;177:156494.
    

    >> Share

    
    
65. ZHU R, Guo J, Huttunen-Lenz M, Stratton G, et al
    Enduring improvements in hepatic insulin sensitivity predict sustained remission of prediabetes during a 3-year lifestyle intervention: results from the PREVIEW multinational diabetes prevention trial.
    Metabolism. 2026;178:156546.
    

    >> Share

    
    
66. LIU P, Shen N, Zhou Y, Wu J, et al
    PFKFB3 nuclear translocation improves diabetic retinopathy by attenuating endothelial cell senescence through inhibition of USP7-p53 axis.
    Metabolism. 2026;178:156553.
    

    >> Share

    
    

    
    Ophthalmol Retina

67. HONG AT, Lin F, Keenan JD, Stewart JM, et al
    Ocular Outcomes with Tirzepatide Versus Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes.
    Ophthalmol Retina. 2026 Feb 6:S2468-6530(26)00046.
    

    >> Share

    
    
68. NI R, Momenaei B, Mahmoudzadeh R, Salabati M, et al
    Eyes Achieving Absence of Diabetic Macular Edema and Very Good Vision: A Post Hoc Analysis of DRCR Network Protocol AC.
    Ophthalmol Retina. 2026 Feb 10:S2468-6530(26)00054.
    

    >> Share

    
    

    
    Pediatr Diabetes

69. ECKERT AJ, Rosenbauer J, Kamrath C, Sindichakis M, et al
    Is the Current Screening Availability for Early Stages of Type 1 Diabetes in Germany Related to the Population-Based Frequency of Diabetic Ketoacidosis at Clinical Manifestation in Children and Adolescents.
    Pediatr Diabetes. 2026;2026:6905472.
    

    >> Share

    
    

    
    PLoS One

70. DOGRA NS, Geiss MP, Gearinger T, Delmerico A, et al
    Mapping disparities in diabetic eye exam adherence using geographic information systems.
    PLoS One. 2026;21:e0340804.
    

    >> Share

    
    
71. CHAISIWAMONGKOL R, Uppala R, Sitthikarnkha P, Techasatian L, et al
    In-hospital outcomes and associated factors of mortality in thai children with diabetic ketoacidosis: A national data analysis 2015-2023.
    PLoS One. 2026;21:e0342777.
    

    >> Share

    
    
72. OUYANG B, Zhuo H, Han H, Lei Y, et al
    Does menopause influence the association between atherogenic index of plasma and prediabetes? A cross-sectional study in middle-aged Chinese women.
    PLoS One. 2026;21:e0342644.
    

    >> Share

    
    
73. 
    Expression of Concern: Targeting NLRP3 and AIM2 signaling pathways by Viscosol alleviates metabolic dysregulations induced inflammatory responses in diabetic neuro- and nephropathy: An in silico and in vivo study.
    PLoS One. 2026;21:e0342732.
    

    >> Share

    
    
74. EL MOUDDEN I, Amidi A, Sharaf-Alddin R, Bittner MC, et al
    Differential impact of admission type and clinical complexity on diabetes hospitalization costs among African American and hispanic patients in Southeastern Virginia.
    PLoS One. 2026;21:e0342483.
    

    >> Share

    
    
75. AHMED S, Barwick A, Sharma A, Hasan MZ, et al
    Current practice in prescribing footwear and insoles to reduce the risk of neuropathic plantar forefoot ulceration and re-ulceration in people with diabetes.
    PLoS One. 2026;21:e0341594.
    

    >> Share

    
    
76. SALABAT D, Panahi N, Fahimfar N, Saeedi M, et al
    Association of VDR gene polymorphisms with prediabetes and Type 2 diabetes mellitus in a sample of the Iranian population.
    PLoS One. 2026;21:e0339758.
    

    >> Share

    
    
77. MUSTERER S, Vogel M, Kiess W, Richter S, et al
    Cardiac markers in children and adolescents at the onset of type 1 diabetes mellitus.
    PLoS One. 2026;21:e0342397.
    

    >> Share

    
    

    
    Retina

78. ZHU J, Liu J, Chen YX, Yang XW, et al
    Compare Combined Use of Anti-VEGF Drugs During or After PPV for Diabetic Macular Edema Guided by MIOCT.
    Retina. 2026 Feb 3. doi: 10.1097/IAE.0000000000004801.
    

    >> Share

    
    
79. BEGAR PG, Demirel S, Sermet F
    Longitudinal Quantitative Evaluation of Retinal and Choroidal Vasculature in Diabetic Patients with and without Retinopathy Using OCT, OCTA, and Semi-Automated MATLAB Method.
    Retina. 2026 Feb 3. doi: 10.1097/IAE.0000000000004802.
    

    >> Share

    
    
80. ZHENG K, Lu P, Huang J, Chen R, et al
    Non-invasive evaluation of diabetic retinal neovascularization using 24x20 mm ultra-widefield optical coherence tomography angiography.
    Retina. 2026 Jan 30. doi: 10.1097/IAE.0000000000004790.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share